SEC ownership of Nkarta, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001787400.

Comparable stake leader

BlackRock, Inc.

Disclosed value leader

RA CAPITAL MANAGEMENT, L.P.

Comparable rows

50/50

Latest evidence

19 May 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
19 May 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001787400
Issuer location
South San Francisco, CA

Ownership snapshot

Top shareholders of Nkarta, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BlackRock, Inc.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
50/50
Latest evidence
19 May 2026
13F 13D/G 3/4/5 Lead comparable stake: 5% 13D/G row: BlackRock, Inc. Showing 1-8 of 50 holder rows.

Quick read

BlackRock, Inc. leads the comparable SEC ownership view at 5%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership Top 5
BlackRock, Inc. 5%
New Enterprise Associates 15, L.P. 4.9%
Samsara BioCapital, L.P. 4.9%
CITADEL ADVISORS LLC 4.1%
LSP 6 Holding C.V. 4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BlackRock, Inc.
13F 13D/G
Company
5%
from 13D/G
$9,512,878
4,508,473 shares
31 Mar 2026
New Enterprise Associates 15, L.P.
13D/G
4.9%
$10,420,841
3,568,781 shares
$0 19 May 2026
Samsara BioCapital, L.P.
13D/G
4.9%
$8,383,322
3,507,666 shares
$0 20 Nov 2025
CITADEL ADVISORS LLC
13D/G 13F
Kenneth Griffin · Company
4.1%
$6,003,741
2,900,358 shares
$0 30 Sep 2025
LSP 6 Holding C.V.
13D/G
LSP 6 Management B.V.
4%
$5,985,097
2,836,539 shares
$0 12 Feb 2025
TANG CAPITAL MANAGEMENT LLC
13F 13D/G
Company
2.1%
from 13D/G
$3,124,537
1,480,823 shares
31 Mar 2026
Commodore Capital LP
13D/G
0.5%
$742,399
351,848 shares
$0 31 Dec 2024
RA CAPITAL MANAGEMENT, L.P.
13F 3/4/5
Company · Director, 10%+ Owner
15%
$22,798,822
10,805,129 shares
31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$70,422.

Buys
$0
Insiders: 0
Sells
$70,422
Insiders: 2
Net
-$70,422
Shares: -33,471
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 33,471
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 1,776 $0 $4,813 -$4,813
3-6 0 0 $0 $0 $0
6-9 0 31,695 $0 $65,609 -$65,609
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 24 reporting-owner rows connected to Nkarta, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
24
Largest Forms 3/4/5 holder
Paul J. Hastings
Net 12M change
-$70,421
Latest report
18 Jun 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Paul J. Hastings Chief Executive Officer, Director $1,057,569 -$58,728 -5.3% Filing P/S 18 Jun 2026
James Trager Chief Scientific Officer $845,370 Filing P/S 18 Jun 2024
David Shook Chief Medical Officer, Head of Research & Development $420,101 Filing P/S 15 Jan 2025
Nadir Mahmood President $347,194 -$11,693 -3.3% Filing P/S 15 Jan 2026
Alicia J. Hager Chief Legal Officer $322,817 Filing P/S 15 Jan 2025
Ralph Brandenberger Chief Technical Officer $274,551 Filing P/S 15 Jan 2025
Alyssa Levin Chief Financial and Business Officer $225,856 Filing P/S 15 Jan 2025
Shawn Marshall Rose Chief Medical Officer, Head of Research & Development $134,169 Mixed 06 Jan 2026
Kanya Rajangam Chief Medical Officer $111,872 Mixed 14 Jan 2022
Tiba Aynechi Director Mixed 08 Jun 2022
Leone D. Patterson Director Mixed 10 Jun 2026
RA Capital Healthcare Fund LP Director, 10%+ Owner Mixed 10 Jun 2026
RA Capital Nexus Fund, L.P. Director Mixed 10 Jun 2026
Peter Kolchinsky Director, 10%+ Owner Mixed 10 Jun 2026
Fouad Oscar Azzam Director Mixed 07 Jun 2023
Rajeev M. Shah Director, 10%+ Owner Mixed 10 Jun 2026
George Vratsanos Director Mixed 10 Jun 2026
Michael Dybbs Director Mixed 10 Jun 2026
Angela Thedinga Director Mixed 10 Jun 2026
Laura Shawver Director Mixed 08 Jun 2022

Recent insider transactions for Nkarta, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Paul J. Hastings NKTX Common Stock Sale -0.45% $4,813 $2.71 -1,776 390,247 18 Jun 2026 Direct
RA CAPITAL MANAGEMENT, L.P. NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 See Footnotes
RA CAPITAL MANAGEMENT, L.P. NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 See Footnotes
Ra Capital Management, L.P. NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 See Footnotes
Ra Capital Management, L.P. NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 See Footnotes
Ra Capital Management, L.P. NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 See Footnotes
Ali Behbahani NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 Direct
Simeon George NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 Direct
George Vratsanos NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 Direct
Zachary Scheiner NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 Direct
Leone D. Patterson NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 Direct
Michael Dybbs NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 Direct
Angela Thedinga NKTX Stock Option (right to buy) Award 37,000 37,000 10 Jun 2026 Direct
Paul J. Hastings NKTX Common Stock Sale -6.26% $53,915 $2.07 -26,046 390,023 15 Jan 2026 Direct
Nadir Mahmood NKTX Common Stock Sale -3.26% $11,693 $2.07 -5,649 167,727 15 Jan 2026 Direct
Shawn Marshall Rose NKTX Common Stock Award 70,000 70,000 06 Jan 2026 Direct
Shawn Marshall Rose NKTX Stock Option (right to buy) Award 139,000 139,000 06 Jan 2026 Direct
Nadir Mahmood NKTX Common Stock Award 85.7% 80,000 173,376 06 Jan 2026 Direct
Nadir Mahmood NKTX Stock Option (right to buy) Award 160,000 160,000 06 Jan 2026 Direct
Paul J. Hastings NKTX Common Stock Award 29.2% 94,000 416,069 06 Jan 2026 Direct
Paul J. Hastings NKTX Stock Option (right to buy) Award 562,000 562,000 06 Jan 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .